Dublin, Oct. 05, 2018 (GLOBE NEWSWIRE) -- The "Global In Vitro Toxicology Testing Market (Drivers, Restraints, Opportunities, Trends and Forecast) 2018-2024" report has been added to ResearchAndMarkets.com's offering.

The global in vitro toxicology testing market is estimated to witness a CAGR of 8.2% during the forecast period 2018-2024.

The market for in vitro toxicology testing is driven by high opposition to animal testing, increased cost related to animal-based toxicity testing, and increasing R&D expenditure for early stage toxicity testing. Whereas, the lack of in vitro models and decreased adoption rate are limiting the growth of the market to an extent.

Europe is the major shareholder in the global in vitro toxicology testing market, followed by North America. The upsurge in the investments by the European Commission in R&D to develop substitute methods to in vivo testing is driving the demand in this region. Asia Pacific is expected to grow at a high CAGR during the forecast period due to increasing number of contract research organizations offering testing services, advancements in healthcare infrastructure, increasing investments in the biopharmaceutical sector, and upward economic conditions in this region.

The in vitro toxicology testing market, by toxicology endpoints, is segmented into systemic toxicity, cytotoxicity testing, genotoxicity testing, ocular toxicity, organ toxicity, dermal toxicity, neurotoxicity, and others. Among these, systemic toxicity accounted for the highest market share in 2017 due to the availability of a wide range of sub-studies, which ensure total analysis of toxicity and safety margin of the testing compounds.

The in vitro toxicology testing market, by industry type, is segmented into pharmaceutical and biopharmaceutical, cosmetics, chemical, diagnostics, and food industry. The pharmaceutical and biopharmaceutical industry occupied significant market share in 2017 and the cosmetics industry is expected to hold a higher percentage during the forecast period. Increased support of regulatory authorities to use in vitro and in silico methods instead of animal testing to check toxicology is driving the growth of the cosmetic industry.

There is an increase in collaborations between companies on in vitro testing of compounds. For instance, in December 2016, Evotec and Celgene entered into a drug discovery collaboration for neurodegenerative diseases. According to agreement terms, Celgene will use Evotec's unique induced pluripotent stem cell (iPSC) platform that enables systematic drug screening in patient-derived disease models.

In June 2017, Censo Biotechnologies Ltd. collaborated with Evotec AG to source and provide patient-derived induced pluripotent stem cells to support Evotec's drug discovery iPSC platform. In addition, the companies are also coming up with new products for in vitro testing. For instance, in January 2018, STEMCELL Technologies Inc. released two product lines for organoid research that will enable scientists to create powerful models for studying human disease in the lab.

Key Topics Covered:

1 Industry Outlook

2 Report Outline

3 Market Snapshot

4 Market Outlook

5 Market Characteristics

6 Toxicity endpoints: Market Size and Analysis

7 Industry type: Market Size and Analysis

8 Regions: Market Size and Analysis

9 Competitive Landscape

10 Vendor Profiles

• Laboratory Corporation of America Holdings (LABCORP)
• Charles River Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• Eurofins Scientific
• Agilent Technologies Inc.

11 Companies to Watch For

• SGS SA
• Abbott Laboratories
• GE Healthcare
• BioReliance Corporation (a subsidiary of Merck KGaA)
• BioIVT
• Bio-Rad Laboratories
• Catalent, Inc.
• Evotec AG (Cyprotex plc)
• Gentronix Limited
• Promega Corporation
• Qiagen N.V.

For more information about this report visit https://www.researchandmarkets.com/research/pmxnwl/global_in_vitro?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, In Vitro Diagnostics